Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

SEWOONMEDICAL CO,. LTD.

세운메디칼100700KOSDAQSector: Pharma & Biotech
₩2,4701.65%Market cap ₩108.2BAs of Sep 4, 2026 close · updated once daily
Market cap
₩108.2B
#682 in KOSDAQ
9.1x
Sector median 15.7x (profitable cos.)
0.72x
Sector median 1.59x
0.0%
Sector median 0.0%
A
Grade A74.5 ptsTop 5% of 2,522 graded stocksMethodology v2.0
Financial strength
89.4/100
Growth momentum
48.1/100
Price attractiveness
82.0/100
Shareholder Return
37.5/100

As of Sep 4, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SACurrentBCDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,522 graded stocks and is currently in band A with a total score of 74.5 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩2,075High ₩3,035
Latest close
Price change by period
1W
2.40%
1M
5.50%
3M
11.70%
1Y
4.80%

As of the Sep 4, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

89.4/100
How much debt does it carry relative to equity?
6.1%
Sector median 51.6%
Sector lowhighTop 6.3% in sector
Can it cover what's due within a year?
1458.0%
Sector median 191.7%
Sector lowhighTop 9.9% in sector
How much of revenue becomes profit?
20.0%
Sector median -2.4%
Sector lowhighTop 7.6% in sector
How much did it earn on its own capital?
7.9%
Sector median -4.5%
Sector lowhighTop 18.8% in sector

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

48.1/100
How much did revenue grow in a year?
5.8%
Sector median 6.4%
Sector lowhighBottom 47% in sector
Has it grown steadily over three years?
1.9%
Sector median 4.9%
Sector lowhighBottom 38.7% in sector
Did core profits grow in a year?
11.6%
Sector median 3.6%
Sector lowhighTop 43.8% in sector
Are core profits higher than three years ago?
4.2%
Sector median 3.5%
Sector lowhighTop 49.7% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

82.0/100
Is the price expensive relative to earnings?
9.1x
Sector median P/E of profitable peers 15.7x · 58% loss-making
Sector lowhighTop 11.9% in sector
Is the price expensive relative to book value?
0.72x
Sector median 1.59x
Sector lowhighTop 24.1% in sector

Valuation uses the Sep 4, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Dividend per share (annual)

Cash dividend per common share as stated in annual reports. ₩0 means no dividend that year.

Dividends & treasury shares

Total cash dividends (FY2025)
₩3.0B
Cash payout ratio, consolidated (FY2025)
24.2%
Treasury shares (FY2025)
1,623,000 shares (3.7% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 7, 2026

Of 9 items: 5 met · 4 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Met
₩11.9B
Positive operating cash flow
Whether cash flow from operations is above zero.
Met
₩17.8B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not met
8.3% → 7.6%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
₩17.8B vs ₩11.9B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Not met
5.0% → 5.8%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Not met
1703.0% → 1458.0%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Met
43,800,000 → 43,800,000
Operating margin up
Whether operating income over revenue rose from the prior year.
Met
18.9% → 20.0%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not met
0.410x → 0.406x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026A

Methodology version change (v2.0 applied)

Jul 15, 2026AVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source ↗
Periodic report filedMay 15, 2026Source ↗

View in the filings calendar →